Two large-scale studies showed modest benefits for daily use of aspirin, NSAIDs.
Daily or almost daily aspirin use modestly reduced ovarian cancer risk among women who took aspirin for less than 10 years, while women already diagnosed with the disease who had recently starting using aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) had a significantly lower risk of ovarian cancer-specific death than never-users, two separate studies indicated.
Both teams said that if the findings are confirmed, the results may support the assessment of aspirin and NSAIDs either as a chemopreventative measure in women not yet diagnosed with ovarian cancer or to improve the prognosis of those who already have the disease.